Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 736

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 736
---
559,944 |   | 4,503,187 |

| * | No amounts were considered as their effects would be anti-dilutive. |

Basic and diluted net loss per share are computed as follows:

| ​                                           | ​ |                  ​ |         ​ | ​ |    ​ |         ​ | ​ |                 ​ |         ​ | ​ |    ​ |         ​ | ​ |
| ​                                           | ​ | Three Months Ended |           |   |      |           | ​ | Nine Months Ended |           |   |      |           | ​ |
| ​                                           | ​ |      September 30, |           |   |      |           | ​ |     September 30, |           |   |      |           | ​ |
| ​                                           |   |               2024 |           |   | 2023 |           |   |              2024 |           |   | 2023 |           | ​ |
| Net loss - basic and diluted                | ​ |                  $ |   -12,476 | ​ |    $ |   -28,032 | ​ |                 $ |   -63,188 | ​ |    $ |   -86,176 | ​ |
| Weighted-average common shares outstanding: | ​ |                    |           | ​ |      |           | ​ |                   |         ​ | ​ |      |           | ​ |
| Basic and diluted                           | ​ |                    | 4,570,320 | ​ |      | 4,519,641 | ​ |                   | 4,559,944 | ​ |      | 4,503,187 | ​ |
| Net loss per share, basic and diluted:      | ​ |                  $ |     -2.73 | ​ |    $ |     -6.20 | ​ |                 $ |    -13.86 | ​ |    $ |    -19.14 | ​ |

As of September 30, 2024,354,964stock options and80,660restricted stock units were outstanding, which could potentially dilute basic earnings per share in the future, but were not included in the computation of diluted net loss per share because to do so would have been anti-dilutive as a result of the net loss for the period.

As of September 30, 2023,670,074stock options and64,643restricted stock units were outstanding, which could potentially dilute basic earnings per share in the future, but were not included in the computation